110 related articles for article (PubMed ID: 2944742)
1. Human acid beta-glucosidase: affinity purification of the normal placental and Gaucher disease splenic enzymes on N-alkyl-deoxynojirimycin-sepharose.
Osiecki-Newman KM; Fabbro D; Dinur T; Boas S; Gatt S; Legler G; Desnick RJ; Grabowski GA
Enzyme; 1986; 35(3):147-53. PubMed ID: 2944742
[TBL] [Abstract][Full Text] [Related]
2. Human acid beta-glucosidase: use of inhibitors, alternative substrates and amphiphiles to investigate the properties of the normal and Gaucher disease active sites.
Osiecki-Newman K; Fabbro D; Legler G; Desnick RJ; Grabowski GA
Biochim Biophys Acta; 1987 Sep; 915(1):87-100. PubMed ID: 2956992
[TBL] [Abstract][Full Text] [Related]
3. Human acid beta-glucosidase: inhibition studies using glucose analogues and pH variation to characterize the normal and Gaucher disease glycon binding sites.
Osiecki-Newman K; Legler G; Grace M; Dinur T; Gatt S; Desnick RJ; Grabowski GA
Enzyme; 1988; 40(4):173-88. PubMed ID: 3234317
[TBL] [Abstract][Full Text] [Related]
4. Human lysosomal beta-glucosidase: purification by affinity chromatography.
Grabowski GA; Dagan A
Anal Biochem; 1984 Aug; 141(1):267-79. PubMed ID: 6437271
[TBL] [Abstract][Full Text] [Related]
5. Human acid beta-glucosidase. Use of conduritol B epoxide derivatives to investigate the catalytically active normal and Gaucher disease enzymes.
Grabowski GA; Osiecki-Newman K; Dinur T; Fabbro D; Legler G; Gatt S; Desnick RJ
J Biol Chem; 1986 Jun; 261(18):8263-9. PubMed ID: 3087971
[TBL] [Abstract][Full Text] [Related]
6. Analyses of catalytic activity and inhibitor binding of human acid beta-glucosidase by site-directed mutagenesis. Identification of residues critical to catalysis and evidence for causality of two Ashkenazi Jewish Gaucher disease type 1 mutations.
Grace ME; Graves PN; Smith FI; Grabowski GA
J Biol Chem; 1990 Apr; 265(12):6827-35. PubMed ID: 2324100
[TBL] [Abstract][Full Text] [Related]
7. Use of activators and inhibitors to define the properties of the active site of normal and Gaucher disease lysosomal beta-glucosidase.
Gatt S; Dinur T; Osiecki K; Desnick RJ; Grabowski GA
Enzyme; 1985; 33(2):109-19. PubMed ID: 3924590
[TBL] [Abstract][Full Text] [Related]
8. Isolation of a cytosolic beta-glucosidase from calf liver and characterization of its active site with alkyl glucosides and basic glycosyl derivatives.
Legler G; Bieberich E
Arch Biochem Biophys; 1988 Jan; 260(1):427-36. PubMed ID: 2963589
[TBL] [Abstract][Full Text] [Related]
9. Purification by affinity chromatography of glucosidase I, an endoplasmic reticulum hydrolase involved in the processing of asparagine-linked oligosaccharides.
Hettkamp H; Legler G; Bause E
Eur J Biochem; 1984 Jul; 142(1):85-90. PubMed ID: 6235111
[TBL] [Abstract][Full Text] [Related]
10. [Separation by electrofocusing of the molecular forms of splenic beta-glucosidase in normal subjects and Gaucher's disease].
Maret A; Salvayre R; Nègre A; Douste-Blazy L
Biomedicine; 1980 May; 33(3):82-6. PubMed ID: 6778520
[TBL] [Abstract][Full Text] [Related]
11. Gaucher's disease II. Studies on the kinetics of beta-glucosidase and the effects of sodium taurocholate in normal and Gaucher tissues.
Choy FY; Davidson RG
Pediatr Res; 1980 Jan; 14(1):54-9. PubMed ID: 6767218
[TBL] [Abstract][Full Text] [Related]
12. N-methyl-N-(5-carboxypentyl)-1-deoxynojirimycin, a new affinity ligand for the purification of trimming glucosidase I.
Bause E; Gross A; Schweden J
FEBS Lett; 1991 Jan; 278(2):167-70. PubMed ID: 1825064
[TBL] [Abstract][Full Text] [Related]
13. Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts.
Bergmann JE; Grabowski GA
Am J Hum Genet; 1989 May; 44(5):741-50. PubMed ID: 2495719
[TBL] [Abstract][Full Text] [Related]
14. Electrophoretic separation of neutral and acid beta-glucosidase isozymes in human tissues.
Shafit-Zagardo B; Devine EA; Desnick RJ
Biochim Biophys Acta; 1980 Aug; 614(2):459-65. PubMed ID: 6773581
[TBL] [Abstract][Full Text] [Related]
15. Beta-glucosidase activity in liver, spleen and brain in acute neuropathic Gaucher disease.
Takahashi T; Nishio H; Kodama S; Nakamura H
Brain Dev; 1990; 12(2):202-5. PubMed ID: 2113779
[TBL] [Abstract][Full Text] [Related]
16. The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen.
Aerts JM; Donker-Koopman WE; van der Vliet MK; Jonsson LM; Ginns EI; Murray GJ; Barranger JA; Tager JM; Schram AW
Eur J Biochem; 1985 Aug; 150(3):565-74. PubMed ID: 4018098
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity in human acid beta-glucosidase revealed by cellulose-acetate electrophoresis.
Sa Miranda MC; Aerts JM; Pinto RA; Magalhaes JA; Barranger JA; Tager JM; Schram AW
Biochim Biophys Acta; 1988 May; 965(2-3):163-8. PubMed ID: 3130106
[TBL] [Abstract][Full Text] [Related]
18. A heterogeneous beta-D-glucosidase activator from monkey parotid gland and its use as an affinity ligand in the purification of human salivary beta-D-glucosidase.
Nagarajan S; Cherian R; Balasubramanian AS
Biochem Int; 1987 Feb; 14(2):365-73. PubMed ID: 3107568
[TBL] [Abstract][Full Text] [Related]
19. In vitro detergent activation of lysosomal acid beta-glucosidase in the spleen of normal and type 1 Gaucher patients is not accompanied by change in aggregation state.
Maret A; Potier M; Salvayre R; Troly M; Beauregard G; Douste-Blazy L
Biochim Biophys Acta; 1989 Jul; 996(3):254-6. PubMed ID: 2502183
[TBL] [Abstract][Full Text] [Related]
20. Physical and kinetic properties of beta-glucosidase in Gaucher disease.
Karazeh A; Carroll M
J Inherit Metab Dis; 1983; 6(3):101-4. PubMed ID: 6422137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
